Welcome to our dedicated page for Evotec news (Ticker: EVO), a resource for investors and traders seeking the latest updates and insights on Evotec stock.
Evotec SE (NASDAQ: EVO; Frankfurt: EVT) is a life science company focused on drug discovery and development, and its news flow reflects ongoing activity across partnerships, platforms and biologics. Company updates frequently highlight progress in strategic collaborations, such as multi-target kidney disease programs with Bayer, protein degradation and neuroscience alliances with Bristol Myers Squibb, and technology-focused agreements with Sandoz.
Investors following EVO news can expect announcements on clinical and preclinical milestones, including the advancement of monoclonal antibody programs into Phase 2 trials and Investigational New Drug acceptances for molecular glue degraders. Evotec also reports on grants and global health initiatives, for example Gates Foundation support for Just - Evotec Biologics’ J.MD™ molecular design service to improve the developability and affordability of monoclonal antibodies for infectious diseases.
News from Just - Evotec Biologics often centers on biologics development, continuous manufacturing technologies and the evolution of its asset-lighter model. This includes transactions such as the sale of the Toulouse site to Sandoz combined with an indefinite license to Evotec’s continuous manufacturing platform, as well as updates on revenue growth with a broadened customer base.
Regular corporate communications also cover financial results, guidance updates, cost reduction initiatives and organizational changes, such as segment renaming to Discovery & Preclinical Development and senior leadership appointments in communications and investor relations. For readers tracking EVO stock, this news page provides a consolidated view of how Evotec’s partnerships, platforms and strategic transactions are progressing over time.
Evotec SE has received an unsolicited, non-binding expression of interest from US biotechnology company Halozyme Therapeutics Inc. regarding a potential takeover. The proposed offer price is EUR 11.00 per share. Evotec states that there was no prior contact before this expression of interest. The company will analyze the proposal and inform the capital market about next steps in accordance with legal requirements.
Halozyme (NASDAQ: HALO) has submitted a non-binding proposal to acquire Evotec SE (NASDAQ: EVO) for €11.00 per share in cash, valuing the company at €2.0 billion. The offer represents a 109% premium to Evotec's share price on October 15, 2024, and a 77% premium to its three-month volume weighted average price.
The proposed combination aims to create a global innovative services company, integrating Evotec's drug discovery platform and Just – Evotec Biologics manufacturing capabilities with Halozyme's ENHANZE® technology. The merger would diversify and extend Halozyme's revenue and EBITDA growth well into the next decade, with no financing contingency required for the transaction.
Evotec SE reported its Q3 2024 financial results, showing mixed performance. Group revenues decreased by 1% to €575.7m, with Total Shared R&D revenues declining 12% to €447.1m due to challenging market conditions. However, Just - Evotec Biologics segment showed strong growth of 74% YoY, contributing €128.7m. The company reported adjusted Group EBITDA of €(6.0)m compared to €50.2m in 9M 2023.
Notable developments include extended partnerships with Bristol Myers Squibb, Sandoz, and Novo Nordisk, plus a new collaboration with Pfizer. The company's Priority Reset program is on track to deliver €40m in annual EBITDA improvements. Evotec maintains its 2024 guidance with revenue expected at €790-820m and adjusted EBITDA at €15-35m.
Evotec SE has announced the sale of its chemical API manufacturing site, Evotec DS GmbH in Halle/Westphalia, to Monacum Partners GmbH. The divestment is part of Evotec's 'Priority Reset' initiative launched in April 2024, aimed at fostering profitable growth through operational refinement. The facility, which specializes in chemical APIs, intermediates, and building blocks manufacturing, will continue operations under the new name DAPIN GmbH. The entire workforce will transition to the new ownership, with Monacum Partners committed to maintaining and growing the business. Financial details were not disclosed.
Evotec SE has announced it will release its financial results for the first nine months of 2024 on Wednesday, November 6, 2024. The company will host a conference call at 2:00 PM CET to discuss the nine-month results and provide updates on their ongoing priority reset and strategic review process. The call will be conducted in English and will include both a webcast and phone-in options. Participants can access presentation slides and register for the audio webcast through provided links. An on-demand version will be available on Evotec's website after the event.
Evotec SE announced progress in its strategic partnership with Bristol Myers Squibb for molecular glue degraders development. The expansion beyond oncology triggered a US$ 50 million payment to Evotec. The collaboration, initiated in 2018 and expanded in 2022, focuses on developing compounds from Bristol Myers Squibb's CELMoDs™ library. The partnership aims to maintain leadership in the field by creating novel molecular glue degraders for high-value targets, emphasizing therapeutic applications beyond oncology with significant unmet medical needs.
Evotec SE (Frankfurt Stock Exchange: EVT, NASDAQ: EVO) has entered into a technology development partnership with Novo Nordisk in cell therapy. The collaboration aims to support the development of next-generation off-the-shelf cell therapy products for clinical development and potential commercialization.
Novo Nordisk will provide funding for technology development activities at Evotec's R&D site in Göttingen, Germany, and at Evotec's certified cell therapy manufacturing facility in Modena, Italy. Novo Nordisk has an option to obtain exclusive rights to use the collaboration results for a pre-defined therapeutic area.
Evotec will receive R&D funding, an undisclosed upfront payment, and potential milestone and royalty payments. The partnership focuses on developing advanced technologies to support stem cell-based therapies, which have shown promise in becoming functional cures for many diseases.
Just - Evotec Biologics, part of Evotec SE, has opened its J.POD® Toulouse, France (EU) facility, marking a significant milestone in biologics manufacturing. This 15,000 sqm facility is the first of its kind in Europe, utilizing advanced continuous manufacturing technology to provide flexible and cost-effective clinical and commercial biologics production.
The facility was built in just 18 months and can produce up to 2 metric tons of biotherapeutics. It features quality control and process development labs, a warehouse, and collaborative office spaces. The J.POD® technology offers a paradigm shift in biomanufacturing, addressing challenges in scaling from clinical to commercial production.
The project received support from the French government, Occitanie Region, Bpifrance, Haute-Garonne prefecture, and Toulouse Métropole. It aims to make biotherapeutics more accessible worldwide while offering enhanced environmental sustainability.
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and X-Chem have announced a collaboration agreement to accelerate early-stage drug discovery. X-Chem will provide access to its DNA-encoded library (DEL) technology, including DELflex and HITMiner, which can screen billions of DNA-tagged compounds simultaneously. This partnership aims to combine X-Chem's DEL technology with Evotec's screening platforms to identify potential drug candidates more efficiently for innovative biological targets.
The collaboration highlights the importance of partnerships in addressing the complexity of drug discovery. Both companies' CEOs expressed enthusiasm about the potential of this collaboration to enhance drug discovery processes and tackle challenging biological targets.
Evotec SE (Frankfurt Stock Exchange: EVT, NASDAQ: EVO) announced that Dr Matthias Evers, Chief Business Officer, will step down effective 01 October 2024 to pursue opportunities outside the company. Evers, appointed on 01 May 2022, played a important role in establishing Evotec's biologics segment Just - Evotec Biologics and aiding the company's recovery from a cyber-attack. The Supervisory Board expressed gratitude for his contributions during challenging times.
Following Evers' departure, the responsibilities of the CBO function will be distributed across other Management Board functions. Dr Christian Wojczewski, CEO of Evotec, thanked Evers for his commitment and leadership, particularly highlighting his support during the transition period.